CASI Pharmaceuticals, Inc. (CASI) financial statements (2021 and earlier)

Company profile

Business Address 9620 MEDICAL CENTER DR
ROCKVILLE, MD 20850
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments6654854327511
Cash and cash equivalents5754844327511
Short-term investments911    
Receivables51    0
Inventory, net of allowances, customer advances and progress billings150    
Inventory150    
Other undisclosed current assets2170000
Total current assets:7462934427611
Noncurrent Assets
Operating lease, right-of-use asset99
Property, plant and equipment2121000
Long-term investments and receivables2914     
Long-term investments2914     
Intangible assets, net (including goodwill)131719    
Intangible assets, net (excluding goodwill)131719    
Other noncurrent assets0100000
Total noncurrent assets:5441211000
TOTAL ASSETS:1281031134528611
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities4823111
Accounts payable4512111
Accrued liabilities 311000
Debt1 1    
Due to related parties   2   
Deferred revenue and credits   0
Other undisclosed current liabilities3     (0)
Total current liabilities:8845111
Noncurrent Liabilities
Long-term debt and lease obligation1  1111
Long-term debt, excluding current maturities   1111
Operating lease, liability1 
Liabilities, other than long-term debt1410 499
Other liabilities1410    
Derivative instruments and hedges, liabilities    499
Other undisclosed noncurrent liabilities1      
Total noncurrent liabilities:1610161111
Total liabilities:2494771212
Temporary equity, carrying amount2221     
Stockholders' equity
Stockholders' equity attributable to parent, including:82731093921(6)(0)
Common stock1111100
Treasury stock, value(8)(8)(8)(8)(8)(8)(8)
Additional paid in capital658607597499470434433
Accumulated other comprehensive income (loss)1(3)(1)    
Accumulated deficit(571)(524)(479)(453)(442)(432)(425)
Warrants and rights outstanding      9
Other undisclosed stockholders' equity attributable to parent      (9)
Total stockholders' equity:82731093921(6)(0)
TOTAL LIABILITIES AND EQUITY:1281031134528611

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues154   00
Revenue, net  00
Cost of revenue(11)(9)(0)  (0)(20)
Cost of goods and services sold(10)(4)   (0)(0)
Gross profit:4(4)(0)  0(20)
Operating expenses(56)(43)(27)(11)(9)(7)(7)
Operating loss:(52)(47)(27)(11)(9)(7)(26)
Nonoperating income (expense)(1)1     
Foreign currency transaction gain (loss), before tax(1)1     
Interest and debt expense(0)(0)(0)    
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes51(0)0   
Loss from continuing operations before equity method investments, income taxes:(48)(45)(27)(11)(9)(7)(26)
Other undisclosed loss from continuing operations before income taxes      (0)
Net loss:(48)(45)(27)(11)(9)(7)(26)
Net income attributable to noncontrolling interest10     
Other undisclosed net loss attributable to parent(2)(1)  (0)(0) 
Net loss available to common stockholders, diluted:(48)(46)(27)(11)(9)(7)(26)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(48)(45)(27)(11)(9)(7)(26)
Other undisclosed comprehensive income (loss)4(2)     
Comprehensive loss:(44)(47)(27)(11)(9)(7)(26)
Comprehensive income, net of tax, attributable to noncontrolling interest00     
Other undisclosed comprehensive loss, net of tax, attributable to parent  (1)    
Comprehensive loss, net of tax, attributable to parent:(43)(46)(29)(11)(9)(7)(26)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: